Impact of Community Treatment With Ivermectin for the Control of Scabies on the Prevalence of Antibodies to Strongyloides stercoralis in Children
Michael Marks, Sarah Gwyn, Hilary Toloka, Christian Kositz, James Asugeni, Rowena Asugeni, Jason Diau, John M Kaldor, Lucia Romani, Michelle Redman-MacLaren, David MacLaren, Anthony W Solomon, David CW Mabey, Andrew C Steer, Diana Martin
CLINICAL INFECTIOUS DISEASES | OXFORD UNIV PRESS INC | Published : 2020
The prevalence of antibodies to Strongyloides stercoralis was measured in 0-12-year-olds using a bead-based immunoassay before and after ivermectin mass drug administration (MDA) for scabies in the Solomon Islands. Seroprevalence was 9.3% before and 5.1% after MDA (P = .019), demonstrating collateral benefits of ivermectin MDA in this setting.
Awarded by Wellcome Trust, Clinical PhD Fellowship
The study was supported by a Wellcome Trust, Clinical PhD Fellowship (grant number 102807 to M. M.). The US Centers for Disease Control and Prevention paid the laboratory costs.